Lido Advisors 13F: Cuts AstraZeneca (AZN) Stake by $17M

Lido Advisors has significantly reduced its stake in AstraZeneca PLC (NYSE:AZN), cutting its holdings by 68% according to its latest 13F filing with the SEC. The firm sold 89,689 shares during the reporting period, leaving it with 42,073 shares valued at approximately $7.8 million.

What Changed in Lido Advisors' AstraZeneca Position

Lido Advisors trimmed its AstraZeneca holdings from 131,762 shares to 42,073 shares, a sharp 68% decrease. This reduction leaves the firm with shares worth about $7.8 million as of the filing date.

Other Institutional Activity in AstraZeneca

Several other institutions have also adjusted their positions in AstraZeneca. INVESTOR AB opened a new position with 51,587,810 shares valued at $10.17 billion. VANGUARD CAPITAL MANAGEMENT LLC also initiated a stake, acquiring 45,040,142 shares worth $8.81 billion. CAPITAL INTERNATIONAL INVESTORS increased its holdings by 19,871,935 shares, a 136.8% rise, bringing its total to 34,393,013 shares valued at $6.72 billion. FMR LLC added 7,752,869 shares, a 35.5% increase, to hold 29,601,724 shares valued at $5.80 billion. Meanwhile, CAPITAL WORLD INVESTORS expanded its stake massively by 27,350,501 shares, marking a 2992.1% increase, reaching 28,264,580 shares worth $5.52 billion.

AstraZeneca PLC Stock Up 13.8%

As of Friday, shares of AstraZeneca were trading around $185.68. The company, which operates in the healthcare sector focusing on drug manufacturing, boasts a market cap of $288 billion. AstraZeneca has a P/E ratio of 27.92 and a forward P/E of 23.09, indicating investor expectations for future earnings growth. The stock's 52-week range spans from $137.22 to $212.71, with a 50-day moving average of $185.29 and a 200-day moving average of $182.76. AstraZeneca maintains a current ratio of 0.91 and a quick ratio of 0.70, with a debt-to-equity ratio of 71.82.

Recent Earnings

AstraZeneca reported revenue of $60.44 billion, reflecting a 12.5% growth. The company's earnings per share stood at $6.65, with a net margin of 17.19% and a return on equity of 23.48%. AstraZeneca is scheduled to release its next earnings report on July 27, 2026.

Dividend

AstraZeneca offers a dividend with an annual rate of $3.16, yielding 1.7%. The company's dividend payout ratio is 47.7%, balancing shareholder returns with reinvestment in growth.

Insider Buying and Selling at AstraZeneca PLC

Insider activity at AstraZeneca has been notable. Sharma Mani, the SVP, Group Controller and Head of Global Finance Services, sold 11,893 shares at an average price of $185.78 on May 20, 2026. Earlier, Mani had made small purchases, acquiring single shares at prices ranging from $179.75 to $196.03. Aradhana Sarin sold 15,000 shares at $88.88 on November 12, 2025.

Analysts Set New Price Targets

Analysts continue to show strong interest in AstraZeneca. Cowen & Co. maintained a buy rating with a $95 target on August 12, 2024. Leerink Partners reiterated a buy rating with a $136 target on July 26, 2024. Jefferies maintained a hold rating, setting a $74 target on July 2, 2024. The consensus among analysts is a strong buy, with a mean target price of $224.49 based on 10 opinions.

About AstraZeneca PLC

AstraZeneca PLC is a global biopharmaceutical company based in Cambridge, United Kingdom. It focuses on the discovery, development, and commercialization of prescription medicines across several therapeutic areas including oncology, cardiovascular, renal, and respiratory diseases. Led by CEO Pascal Soriot, the company employs around 96,100 people and operates in multiple markets worldwide.

Bottom Line

Lido Advisors' decision to cut its AstraZeneca stake by 68% reflects strategic portfolio adjustments as reported in its 13F filing. Investors often track such filings to gauge institutional sentiment, though these reports are backward-looking and may not represent current positions. AstraZeneca remains a significant player in the healthcare sector, with analysts maintaining a strong buy consensus.